Category
January 18, 2023
Jan 17, 2023 | staff reporter NEW YORK – Lantern Pharma on Tuesday said it received feedback from the US Food and Drug Administration that it will use to submit an investigational new drug application for LP-184. The company further plans to begin studying the drug in a Phase I trial of [...]December 15, 2022
Luiz O.F. Penalva, PhD to receive an award from the Mike Hogg Fund in support of his study, “Preventing Senescence Scape to Overcome Tumor Recurrence in Glioblastoma.” Learn more about Dr. Penalva's researchSeptember 20, 2022
Webinar to be hosted on Thursday, Sept. 22, 2022, at 12:00 p.m. ET, register here. Dr. Houghton will discuss challenges in drug development for pediatric cancers and preliminary results from Lantern’s drug candidates in preclinical pediatric cancer models with unmet clinical needs. September 19, 2022 08:50 AM Eastern Daylight Time DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: [...]September 19, 2022
Talk Title: Structured RNAs restrict the N6-adenine methylation (m6dA) activity of human METTL3-METTL14September 19, 2022
Good afternoon, everyone! Please join us and Dr. Alexander J.R. Bishop in congratulating Henry Miller on his passing his PhD Defense with honors! Way to go Henry!!!!! _________________________________________________________ Since 2004, UT Health San Antonio, Greehey Children’s Cancer Research Institute’s (Greehey CCRI) mission has been to advance scientific knowledge relevant to childhood cancer, contribute to understanding its causes, [...]August 31, 2022
Posted on August 29, 2022 at 10:39 am. Shared by Steven Lee Now ranked 12th; fifth among health care/social employers. The University of Texas Health Science Center at San Antonio (UT Health San Antonio) has jumped to 12th on Forbes magazine’s list of Best-In-State Employers 2022, from 34th last year. UT Health San Antonio made the ranking of [...]August 24, 2022
The National Cancer Institute (NCI) has recently awarded an R50 Research Specialist Award to Dr. Zhao Lai, Associate Professor/Research, Director of the Next-Generation Sequencing Shared Resource (NGSSR) in the NCI-designated Mays Cancer Center (MCC). This award, over five years, supports the development of a stable research career for Dr. Lai, an exceptional scientist who will [...]August 9, 2022
During Childhood Cancer Awareness Month in September, Lantern will host a KOL webinar featuring Dr. Peter Houghton, Ph.D., a leading expert in childhood cancers at the Greehey Children's Cancer Institute at the University of Texas San Antonio Health Science Center. The webinar will focus on challenges in drug development for pediatric cancers and preliminary results from [...]June 24, 2022
Abstract Atypical teratoid/rhabdoid tumors (AT/RT) of the brain and malignant rhabdoid tumors of the kidney (RTK) compose a group of highly malignant pediatric cancers known as malignant rhabdoid tumors (MRT). Both subtypes are characterized by the biallelic loss of the SMARCB1 gene (member of the human SWI/SNF complex), which is thought to function as a [...]